Please login to the form below
Exscientia
This page shows the latest Exscientia news and features for those working in and with pharma, biotech and healthcare.
Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies
According to the terms detailed in the agreement, Sanofi will pay Exscientia an upfront cash payment of $100m. ... The companies’ intentions through this collaboration are to accelerate drug discovery and improve clinical access by utilising
Latest news
-
BMS links up with Exscientia for $1.2bn AI drug discovery deal
Exscientia’s application of AI technologies is proving capable of generating best-in-class molecules while also reducing discovery times. ... technologies and drug discovery expertise,” said Andrew Hopkins, chief executive officer of Exscientia.
-
Bayer bulks up in women’s health again with non-hormonal contraceptive deal
UK artificial intelligence company Exscientia focusing on drug discovery for cardiovascular and cancer therapies.
-
Recursion raises $121m for AI-led drug discovery
Numerous other companies are pioneering AI-led drug discovery, including Berg, BenevolentAI, Insilico Medicine and Exscientia. ... In March, Celgene signed a deal with UK-based Exscientia in oncology drug discovery.
-
Data regulations impeding AI use in drug research
Recent weeks have seen more alliances forged in the field, with Celgene working with Exscientia and AstraZeneca partnering with BenevolentAI.
-
Celgene and Exscientia sign AI drug discovery deal in oncology and autoimmunity
Exscientia will use its Centaur Chemist AI drug discovery platform in the collaboration. ... drug discovery,” says professor Andrew Hopkins, ex-Pfizer scientist and CEO of Exscientia.
More from news
Approximately 7 fully matching, plus 6 partially matching documents found.
Latest Intelligence
-
A snapshot of… Exscientia
At Exscientia, we uniquely apply AI and machine learning with experiments in order to accelerate the discovery of new clinic-ready compounds. ... What impact is the planned Brexit having on the company? For Exscientia, access to great talent is vital.
-
AI and genomics: a revolution in drug discovery and development
Likewise, Sanofi has partnered with Exscientia to use its artificial intelligence technology to find potentials targets for metabolic disease therapies.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Janssen’s single tablet combination shows promise in phase 3 PAH study
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- How to make sure your adverts for clinical trials are compliant
PMHub
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
